Treatment of Candida auris Endocarditis
For Candida auris endocarditis, initiate high-dose echinocandin therapy (caspofungin 150 mg daily, micafungin 150 mg daily, or anidulafungin 200 mg daily) OR lipid formulation amphotericin B 3-5 mg/kg daily, combined with urgent cardiac surgery for valve replacement, followed by at least 6 weeks of antifungal therapy post-operatively.
Initial Antifungal Therapy
The IDSA guidelines provide clear direction for Candida endocarditis management, which applies to C. auris given its typical multidrug-resistant profile 1. You have two equally recommended first-line options:
- High-dose echinocandins: Caspofungin 150 mg daily, micafungin 150 mg daily, or anidulafungin 200 mg daily
- Lipid formulation amphotericin B: 3-5 mg/kg daily, with or without flucytosine 25 mg/kg four times daily
Recent evidence supports echinocandins as at least equivalent to amphotericin B for Candida endocarditis, with potentially better safety profiles 2, 3. A 2026 Swedish nationwide cohort found no significant differences in treatment failure rates between echinocandin-based therapy (32%) and amphotericin B-based therapy (38%), despite echinocandin patients being older with more comorbidities 3.
Critical consideration for C. auris: This organism is frequently resistant to fluconazole and often to amphotericin B. Echinocandins typically remain active and should be strongly favored as initial therapy pending susceptibility testing 2.
Surgical Management
Valve replacement is mandatory and should not be delayed 1. The combination of medical and surgical therapy is essential for survival. A meta-analysis of 879 Candida endocarditis cases demonstrated marked mortality reduction with adjunctive valve surgery (prevalence odds ratio 0.56) 4.
Timing considerations:
- Surgery should be performed as soon as the patient is medically stabilized
- Do not wait for prolonged antifungal therapy before surgery
- The high mortality rate (historically >50%) demands aggressive combined intervention
Duration and Step-Down Therapy
Continue antifungal therapy for at least 6 weeks after valve replacement 1. Extend duration longer if perivalvular abscesses or other complications are present.
Step-down therapy options (only if susceptible):
After clinical stability, bloodstream clearance, and confirmed susceptibility:
- Fluconazole 400-800 mg (6-12 mg/kg) daily for susceptible isolates 1
- Voriconazole 200-300 mg (3-4 mg/kg) twice daily OR posaconazole tablets 300 mg daily for azole-susceptible but fluconazole-resistant isolates 1
Major caveat for C. auris: Most C. auris isolates are fluconazole-resistant, making step-down to azoles problematic. You will likely need to continue echinocandin therapy for the full treatment course 2.
Long-Term Suppressive Therapy
For patients who cannot undergo valve replacement, lifelong suppression with fluconazole 400-800 mg daily is recommended if the isolate is susceptible 1. However, given C. auris resistance patterns, this is often not feasible.
For prosthetic valve endocarditis after successful treatment, chronic suppressive antifungal therapy is recommended to prevent recurrence 1.
Special Considerations for C. auris
C. auris presents unique challenges:
- Multidrug resistance: Often resistant to fluconazole and amphotericin B 2
- Echinocandin resistance emerging: Particularly concerning in C. parapsilosis, but also reported in C. auris 2
- Mandatory susceptibility testing: Do not assume susceptibility patterns; obtain antifungal susceptibility testing immediately 2
- Consider combination therapy: In severe cases or with resistance, combination antifungal therapy may be necessary, though evidence is limited
Monitoring Requirements
- Blood cultures: Repeat daily until clearance documented
- Echocardiography: Serial imaging to assess vegetation size and complications
- Ophthalmologic examination: Screen for endophthalmitis, which complicates Candida endocarditis 4
- Monitor for embolic phenomena: Large emboli to major vessels occur more frequently than in bacterial endocarditis 1, 4
Common Pitfalls to Avoid
- Do not use standard-dose echinocandins - endocarditis requires high-dose therapy (150 mg caspofungin, 150 mg micafungin, or 200 mg anidulafungin) 1
- Do not delay surgery - medical therapy alone has unacceptably high failure rates
- Do not assume fluconazole susceptibility - C. auris is typically resistant
- Do not use fluconazole monotherapy - associated with high relapse and mortality rates 1
- Do not stop therapy prematurely - minimum 6 weeks post-surgery, often longer